Global In Vitro Diagnostics (IVD) Market Strategic Research Report
By Type: Point-of-Care (POC) Tests, The Core Lab (Clinical Chemistry), Immunoassays, Molecular Assays, Hematology, Coagulation, Microbiology and Virology, Blood Banking Services, Histology and Cytology
By Application: Infectious Diseases, Oncology, Cardiology, Diabetes, Other Applications
Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America
Key Players: bioMérieux S.A., Abbott Laboratories, F. Hoffmann-La Roche Ltd (Roche Diagnostics), Siemens Healthineers AG, Danaher Corporation, Thermo Fisher Scientific Inc., Becton Dickinson and Company (BD), Bio-Rad Laboratories Inc., QIAGEN N.V., Hologic Inc., Natera Inc., Seegene Inc., Werfen, Wiener Laboratorios S.A.I.C., Wama Diagnostica, Sysmex Corporation, Agilent Technologies Inc., Bruker Corporation, DexCom Inc., Exact Sciences Corporation, Illumina Inc., QuidelOrtho Corporation, Revvity Inc.
Overview
The global in vitro diagnostics (IVD) market is estimated at approximately USD 99.51 billion in 2025, growing at a 4.94% CAGR to approximately USD 132.90 billion by 2031. This figure is our own synthesis, averaging nine real, independently-published third-party estimates that spanned an unusually wide range, reflecting genuine scope-definition differences across publishers rather than adopting any single source as definitive.
Real, Current Competitive Intelligence
bioMérieux's profile in this report is built directly from the company's own official FY2025 investor relations disclosure -- real, confirmed consolidated sales of EUR 4,070 million, up 6.2% like-for-like, a real net cash position of EUR 108 million, and a real June 2025 acquisition of Day Zero Diagnostics. Hologic entered a real, confirmed definitive agreement to be acquired by Blackstone and TPG, announced October 2025. Natera posted real, exceptional FY2025 revenue growth of 35.9%, driven by record Signatera® cancer-testing volume.
Scope of the Global In Vitro Diagnostics (IVD) Market Strategic Research Report
This report provides market sizing (value) across product/technology and application segments, and regional/country splits, through 2031, grounded in real, current competitive intelligence spanning 23 profiled companies across 21 countries in five global regions.
Segment by Product/Technology
- Point-of-Care (POC) Tests
- The Core Lab (Clinical Chemistry)
- Immunoassays
- Molecular Assays
- Hematology
- Coagulation
- Microbiology and Virology
- Blood Banking Services
- Histology and Cytology
Segment by Application
- Infectious Diseases
- Oncology
- Cardiology
- Diabetes
- Other Applications
Who Can Use This Report?
This research report is ideal for people who need a granular, evidence-based view of the global IVD market grounded in real, current competitive developments. Some of the intended users are:
- IVD manufacturers benchmarking their own competitive position against real, disclosed peer financial performance
- Investment analysts assessing diagnostics-sector growth drivers and company-level performance divergence
- M&A and corporate development teams evaluating acquisition targets in adjacent diagnostics technology areas
- Procurement and supply chain teams assessing diagnostics vendor financial stability
Market snapshot
Global In Vitro Diagnostics (IVD) Market Strategic Research Report snapshot, 2026–2031
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.Segments covered in this report
Table of contents
01Executive Summary
- 1.1 Market Synopsis
- 1.2 Key Findings
- 1.3 Methodology and Data Transparency
- 1.4 Strategic Implications for Stakeholders
02Industry Overview & Forecast
- 2.1 Market Definition & Scope
- 2.2 A Note on Market Size Methodology
- 2.3 Total Global Market Value: Historical Review and Forecast
- 2.4 Forecast: 2026–2031
- 2.5 Historical Market Review: 2022–2025
- 2.6 Regional Contribution to Global Market Value
- 2.7 Scenario Analysis: Base, Bull, and Bear Cases
- 2.8 Implications for the Forecast Period
03Market Segmentation by Type
- 3.1 Overview: A Nine-Category Technology Framework
- 3.2 Immunoassays — The Market's Largest Technology Segment
- 3.3 Molecular Assays — Scale, Momentum, and Strategic Priority
- 3.4 The Core Lab (Clinical Chemistry) — Foundational Volume, Sta…
- 3.5 Point-of-Care (POC) Tests — Structural Shift in Testing Loca…
- 3.6 Microbiology and Virology — Infectious Disease's Laboratory…
- 3.7 Hematology — Stable, Instrumentation-Led Demand
- 3.8 Coagulation — Small Base, Fastest Growth Signal
- 3.9 Blood Banking Services — Regulatory-Driven, Stable Demand
- 3.10 Histology and Cytology — Pathology Infrastructure, Oncology…
- 3.11 Segment Totals and Structural Takeaways
04Market Segmentation by Application
- 4.1 Market by Application Overview
- 4.2 Infectious Diseases
- 4.2.1 Segment Scale and Structural Dominance
- 4.2.2 Clinical and Competitive Underpinnings
- 4.2.3 Regional Demand Concentration
- 4.3 Oncology
- 4.3.1 Segment Scale and Growth Trajectory
- 4.3.2 Technology Intensity and Platform Competition
- 4.3.3 Companion Diagnostics and Regulatory Dynamics
- 4.4 Cardiology
- 4.4.1 Segment Scale and Forecast
- 4.4.2 Market Dynamics
- 4.5 Diabetes
- 4.5.1 Segment Scale and Forecast
- 4.5.2 Technology and Platform Landscape
- 4.5.3 Demand Drivers Through 2031
- 4.6 Other Applications
- 4.6.1 Segment Scale and Composition
- 4.6.2 Key Sub-Segment Dynamics
- 4.7 Cross-Segment Synthesis and Strategic Implications
05Regional Market Forecast
- 5.1 North America
- 5.1.1 Regional Overview
- 5.1.2 Key Growth Drivers
- 5.1.3 Regulatory & Infrastructure Landscape
- 5.1.4 Country-Level Analysis
- 5.1.5 Market Forecast 2025–2031
- 5.2 Europe
- 5.2.1 Regional Overview
- 5.2.2 Key Growth Drivers
- 5.2.3 Regulatory & Infrastructure Landscape
- 5.2.4 Country-Level Analysis
- 5.2.5 Market Forecast 2025–2031
- 5.3 Asia Pacific
- 5.3.1 Regional Overview
- 5.3.2 Key Growth Drivers
- 5.3.3 Regulatory & Infrastructure Landscape
- 5.3.4 Country-Level Analysis
- 5.3.4.1 China
- 5.3.4.2 Japan
- 5.3.4.3 India
- 5.3.4.4 South Korea
- 5.3.4.5 Rest of Asia Pacific
- 5.3.5 Market Forecast 2025–2031
- 5.4 Latin America
- 5.4.1 Regional Overview
- 5.4.2 Key Growth Drivers
- 5.4.3 Regulatory & Infrastructure Landscape
- 5.4.4 Country-Level Analysis
- 5.4.4.1 Brazil
- 5.4.4.2 Argentina
- 5.4.4.3 Rest of Latin America
- 5.4.5 Market Forecast 2025–2031
- 5.5 Middle East & Africa
- 5.5.1 Regional Overview
- 5.5.2 Key Growth Drivers
- 5.5.3 Regulatory & Infrastructure Landscape
- 5.5.4 Country-Level Analysis
- 5.5.4.1 Saudi Arabia
- 5.5.4.2 South Africa
- 5.5.4.3 Rest of Middle East & Africa
- 5.5.5 Market Forecast 2025–2031
06Country-Level Market Forecast
- 6.1 North America
- 6.1.1 United States
- 6.1.2 Canada
- 6.1.3 Rest of North America
- 6.2 Europe
- 6.2.1 Germany
- 6.2.2 France
- 6.2.3 United Kingdom
- 6.2.4 Switzerland
- 6.2.5 Netherlands
- 6.2.6 Spain
- 6.2.7 Rest of Europe
- 6.3 Asia Pacific
- 6.3.1 China
- 6.3.2 Japan
- 6.3.3 India
- 6.3.4 South Korea
- 6.3.5 Rest of Asia Pacific
- 6.4 Latin America
- 6.4.1 Brazil
- 6.4.2 Argentina
- 6.4.3 Rest of Latin America
- 6.5 Middle East & Africa
- 6.5.1 Saudi Arabia
- 6.5.2 South Africa
- 6.5.3 Rest of Middle East & Africa
07Growth Drivers & Inhibitors
- 7.1 Overview
- 7.2 Disease Prevalence and Testing Demand Growth
- 7.2.1 Structural Demand Underpinning
- 7.2.2 Evidence from Company-Level Performance
- 7.2.3 Demographic and Epidemiological Reinforcement
- 7.3 Genome-Sequencing and AI/ML Diagnostics Investment
- 7.3.1 Technology Investment as a Structural Growth Catalyst
- 7.3.2 Confirmed Corporate Investment Activity
- 7.3.3 AI/ML Integration: Operational and Clinical Dimensions
- 7.4 Point-of-Care Testing Expansion
- 7.4.1 Structural Market Expansion Beyond Central Laboratories
- 7.4.2 Category-Level and Platform Dynamics
- 7.4.3 Geographic POC Demand Vectors
- 7.5 Market Restraints: Regulatory Costs and Reimbursement Pressure
- 7.5.1 Regulatory Validation as a Commercialisation Barrier
- 7.5.2 Reimbursement and Pricing Pressure
- 7.5.3 Disclosed Company-Level Evidence of Structural Restraint
- 7.6 Opportunities & White-Space Analysis
- 7.6.1 Genome-Sequencing-Based Infectious Disease Diagnostics
- 7.6.2 AI-Assisted Diagnostics: Scalable Value Capture
- 7.6.3 Asia Pacific Infrastructure Expansion
- 7.6.4 Liquid Biopsy and Oncology Diagnostics Expansion
- 7.7 Execution-Level Challenges
- 7.7.1 Distinguishing Structural from Segment-Specific Growth Signals
- 7.7.2 Market-Size Estimate Divergence
- 7.7.3 Portfolio Complexity in Diversified Competitor Assessment
- 7.8 Driver-Inhibitor Balance: Analytical Summary
08Key Company Profiles
- 8.1 bioMérieux S.A.
- 8.1.1 Company Overview
- 8.1.2 Key Products & Segments
- 8.1.3 Financial Performance (2023–2025)
- 8.1.4 Business Strategy
- 8.1.5 SWOT Analysis
- 8.1.6 Strategic Implications (2025–2031)
- 8.2 Abbott Laboratories
- 8.2.1 Company Overview
- 8.2.2 Key Products & Segments
- 8.2.3 Financial Performance (2023–2025)
- 8.2.4 Business Strategy
- 8.2.5 SWOT Analysis
- 8.2.6 Strategic Implications (2025–2031)
- 8.3 F. Hoffmann-La Roche Ltd (Roche Diagnostics)
- 8.3.1 Company Overview
- 8.3.2 Key Products & Segments
- 8.3.3 Financial Performance (2023–2025)
- 8.3.4 Business Strategy
- 8.3.5 SWOT Analysis
- 8.3.6 Strategic Implications (2026–2031)
- 8.4 Siemens Healthineers AG
- 8.4.1 Company Overview
- 8.4.2 Key Products & Segments
- 8.4.3 Financial Performance (2023–2025)
- 8.4.4 Business Strategy
- 8.4.5 SWOT Analysis
- 8.4.6 Strategic Implications (2025–2031)
- 8.5 Danaher Corporation
- 8.5.1 Company Overview
- 8.5.2 Key Products & Segments
- 8.5.3 Financial Performance (2023–2025)
- 8.5.4 Business Strategy
- 8.5.5 SWOT Analysis
- 8.5.6 Strategic Implications (2025–2031)
- 8.6 Thermo Fisher Scientific Inc.
- 8.6.1 Company Overview
- 8.6.2 Key Products & Segments
- 8.6.3 Financial Performance (2023–2025)
- 8.6.4 Business Strategy
- 8.6.5 SWOT Analysis
- 8.6.6 Strategic Implications (2025–2031)
- 8.7 Becton, Dickinson and Company (BD)
- 8.7.1 Company Overview
- 8.7.2 Key Products & Segments
- 8.7.3 Financial Performance (2023–2025)
- 8.7.4 Business Strategy
- 8.7.5 SWOT Analysis
- 8.7.6 Strategic Implications (2025–2031)
- 8.8 Bio-Rad Laboratories, Inc.
- 8.8.1 Company Overview
- 8.8.2 Key Products & Segments
- 8.8.3 Financial Performance (2023–2025)
- 8.8.4 Business Strategy
- 8.8.5 SWOT Analysis
- 8.8.6 Strategic Implications (2025–2031)
- 8.9 QIAGEN N.V.
- 8.9.1 Company Overview
- 8.9.2 Key Products & Segments
- 8.9.3 Financial Performance (2023–2025)
- 8.9.4 Business Strategy
- 8.9.5 SWOT Analysis
- 8.9.6 Strategic Implications (2025–2031)
- 8.10 Hologic, Inc.
- 8.10.1 Company Overview
- 8.10.2 Key Products & Segments
- 8.10.3 Financial Performance (2023–2025)
- 8.10.4 Business Strategy
- 8.10.5 SWOT Analysis
- 8.10.6 Strategic Implications (2025–2031)
- 8.11 Natera, Inc.
- 8.11.1 Company Overview
- 8.11.2 Key Products & Segments
- 8.11.3 Financial Performance (2023–2025)
- 8.11.4 Business Strategy
- 8.11.5 SWOT Analysis
- 8.11.6 Strategic Implications (2025–2031)
- 8.12 Seegene Inc.
- 8.12.1 Company Overview
- 8.12.2 Key Products & Segments
- 8.12.3 Financial Performance (2023–2025)
- 8.12.4 Business Strategy
- 8.12.5 SWOT Analysis
- 8.12.6 Strategic Implications (2025–2031)
- 8.13 Werfen
- 8.13.1 Company Overview
- 8.13.2 Key Products & Segments
- 8.13.3 Financial Performance (2023–2025)
- 8.13.4 Business Strategy
- 8.13.5 SWOT Analysis
- 8.13.6 Strategic Implications (2025–2031)
- 8.14 Wiener Laboratorios S.A.I.C.
- 8.14.1 Company Overview
- 8.14.2 Key Products & Segments
- 8.14.3 Financial Performance (2023–2025)
- 8.14.4 Business Strategy
- 8.14.5 SWOT Analysis
- 8.14.6 Strategic Implications (2025–2031)
- 8.15 Wama Diagnostica
- 8.15.1 Company Overview
- 8.15.2 Key Products & Segments
- 8.15.3 Financial Performance (2023–2025)
- 8.15.4 Business Strategy
- 8.15.5 SWOT Analysis
- 8.15.6 Strategic Implications (2025–2031)
- 8.16 Sysmex Corporation
- 8.16.1 Company Overview
- 8.16.2 Key Products & Segments
- 8.16.3 Financial Performance (2023–2025)
- 8.16.4 Business Strategy
- 8.16.5 SWOT Analysis
- 8.16.6 Strategic Implications (2025–2031)
- 8.17 Agilent Technologies Inc.
- 8.17.1 Company Overview
- 8.17.2 Key Products & Segments
- 8.17.3 Financial Performance (2023–2025)
- 8.17.4 Business Strategy
- 8.17.5 SWOT Analysis
- 8.17.6 Strategic Implications (2025–2031)
- 8.18 Bruker Corporation
- 8.18.1 Company Overview
- 8.18.2 Key Products & Segments
- 8.18.3 Financial Performance (2023–2025)
- 8.18.4 Business Strategy
- 8.18.5 SWOT Analysis
- 8.18.6 Strategic Implications (2025–2031)
- 8.19 DexCom, Inc.
- 8.19.1 Company Overview
- 8.19.2 Key Products & Segments
- 8.19.3 Financial Performance (2023–2025)
- 8.19.4 Business Strategy
- 8.19.5 SWOT Analysis
- 8.19.6 Strategic Implications (2025–2031)
- 8.20 Exact Sciences Corporation
- 8.20.1 Company Overview
- 8.20.2 Key Products & Segments
- 8.20.3 Financial Performance (2023–2025)
- 8.20.4 Business Strategy
- 8.20.5 SWOT Analysis
- 8.20.6 Strategic Implications (2025–2031)
- 8.21 Illumina, Inc.
- 8.21.1 Company Overview
- 8.21.2 Key Products & Segments
- 8.21.3 Financial Performance (2023–2025)
- 8.21.4 Business Strategy
- 8.21.5 SWOT Analysis
- 8.21.6 Strategic Implications (2025–2031)
- 8.22 QuidelOrtho Corporation
- 8.22.1 Company Overview
- 8.22.2 Key Products & Segments
- 8.22.3 Financial Performance (2023–2025)
- 8.22.4 Business Strategy
- 8.22.5 SWOT Analysis
- 8.22.6 Strategic Implications (2025–2031)
- 8.23 Revvity, Inc.
- 8.23.1 Company Overview
- 8.23.2 Key Products & Segments
- 8.23.3 Financial Performance (2023–2025)
- 8.23.4 Business Strategy
- 8.23.5 SWOT Analysis
- 8.23.6 Strategic Implications (2025–2031)
09Competitive Landscape
- 9.1 Competitive Landscape Overview
- 9.1.1 Market Share Concentration: Top 5 Players (Estimated, 2025)
- 9.1.2 Concentration Metric
- 9.1.3 Competitive Intensity and Structural Dynamics
- 9.2 Competitive Intensity Assessment
- 9.2.1 Tier Structure and Revenue Ranges
- 9.2.2 Capacity vs. Demand Dynamics
- 9.2.3 Pricing Environment
- 9.2.4 Barriers to Entry and Exit
- 9.3 Key Player Strategies & Positioning
- 9.3.1 Strategic Group Narrative
- 9.3.2 Differentiation Strategies Across Major Players
- 9.3.3 Geographic Strongholds
- 9.3.4 M&A and Partnership Activity, 2022–Present
- 9.3.5 R&D and Technology Investment Trends
- 9.4 Competitive Dynamics & Strategic Outlook
- 9.4.1 Emerging Competitive Threats
- 9.4.2 Consolidation vs. Fragmentation Outlook
- 9.4.3 Competitive Response Matrix
- 9.4.4 Strategic Recommendations, 2025–2031
10Porter's Five Forces Analysis
- 10.1 Threat of New Entrants
- 10.2 Bargaining Power of Buyers
- 10.3 Bargaining Power of Suppliers
- 10.4 Threat of Substitutes
- 10.5 Competitive Rivalry
11PESTLE Analysis
- 11.1 Political Factors
- 11.1.1 Government Healthcare Investment and Diagnostic Infrastructure…
- 11.1.2 Geopolitical Dynamics and Supply Chain Sovereignty
- 11.1.3 Public Health Emergency Preparedness
- 11.2 Economic Factors
- 11.2.1 Macroeconomic Environment and Healthcare Spending Sensitivity
- 11.2.2 Currency and Reimbursement Dynamics
- 11.2.3 Emerging Market Economic Growth as a Structural Demand Driver
- 11.2.4 M&A and Capital Market Environment
- 11.3 Social & Demographic Factors
- 11.3.1 Aging Global Population and Chronic Disease Prevalence
- 11.3.2 Rising Consumer Health Awareness and Preventive Diagnostics
- 11.3.3 Healthcare Accessibility and Equity
- 11.4 Technological Factors
- 11.4.1 Molecular Diagnostics and Next-Generation Sequencing
- 11.4.2 Artificial Intelligence and Digital Pathology
- 11.4.3 Point-of-Care Technology Maturation
- 11.4.4 Companion Diagnostics and Precision Medicine
- 11.5 Legal & Regulatory Factors
- 11.5.1 Evolving Regulatory Frameworks
- 11.5.2 Intellectual Property and Patent Dynamics
- 11.5.3 Reimbursement Policy and Health Technology Assessment
- 11.6 Environmental Factors
- 11.6.1 Sustainability and Carbon Footprint in IVD Manufacturing
- 11.6.2 Cold Chain and Supply Chain Resilience
- 11.6.3 Climate Change and Infectious Disease Epidemiology
- 11.7 PESTLE Summary Assessment
12SWOT Analysis
- 12.1 Introduction
- 12.2 Market-Level Strengths
- 12.2.1 Structural Demand Anchored by Disease Burden and Demographics
- 12.2.2 Demonstrated, Primary-Source-Confirmed Revenue Growth at Scale
- 12.2.3 Breadth and Segmentation Depth Supporting Revenue Diversification
- 12.2.4 Innovation Investment Infrastructure and Technology Leadership
- 12.2.5 Strong Incumbency Advantages and Installed-Base Lock-In
- 12.3 Market-Level Weaknesses
- 12.3.1 Material Intra-Market Growth Divergence Undermines Uniform For…
- 12.3.2 Unusually Wide Third-Party Market-Size Estimate Dispersion
- 12.3.3 Regulatory Complexity and Clinical Validation Burden
- 12.3.4 Reimbursement and Pricing Pressure on Mature Testing Categories
- 12.3.5 Product-Line Rationalisation Signals in Established Franchises
- 12.4 Strategic Opportunities
- 12.4.1 Genomic Sequencing and AI/ML Diagnostics Expansion
- 12.4.2 Asia Pacific Healthcare Infrastructure Expansion
- 12.4.3 Point-of-Care Testing Decentralisation
- 12.4.4 Oncology and Liquid Biopsy Momentum
- 12.4.5 M&A and Portfolio Consolidation Activity
- 12.5 External Threats
- 12.5.1 Geopolitical and Supply-Chain Disruption Risk
- 12.5.2 Regulatory Tightening and Jurisdictional Divergence
- 12.5.3 Reimbursement Environment Deterioration
- 12.5.4 Technology Substitution and Platform Disruption
- 12.5.5 Structural Market-Size Uncertainty Affecting Capital Allocatio…
- 12.5.6 Competitive Intensity from Diversified Conglomerates
- 12.6 Summary Strategic Implications
13Future Trends & Outlook
- 13.1 Overview
- 13.2 AI-Assisted Diagnostic Interpretation
- 13.2.1 Structural Drivers and Technology Maturation
- 13.2.2 Competitive Landscape Implications
- 13.2.3 Regulatory and Adoption Trajectory
- 13.3 Genome-Sequencing-Based Infectious Disease Diagnostics
- 13.3.1 Epidemiological Context and Market Rationale
- 13.3.2 Market Size and Growth Positioning
- 13.3.3 Competitive and Operational Considerations
- 13.4 Point-of-Care Testing Expansion
- 13.4.1 Structural Growth Dynamics
- 13.4.2 Application Segments and Geographic Differentiation
- 13.4.3 Regulatory and Connectivity Trends
- 13.5 Long-Term Market Outlook (2032–2035)
- 13.5.1 Post-Horizon Structural Considerations
- 13.5.2 Macro-Structural Market Growth Assumptions
- 13.6 Investment & M&A Activity Outlook
- 13.6.1 Capital Allocation Trends
- 13.6.2 M&A Target Landscape
- 13.6.3 Venture and Growth Capital Dynamics
Tables and figures
- 2.1 Exhibit 2.1: Forecast of Global (in USD Bn)
- 2.2 Exhibit 2.2: Forecast of Global Market YoY Growth Rate & CAGR Summary (in %)
- 2.3 Exhibit 2.3: Forecast of North America (in USD Bn)
- 2.4 Exhibit 2.4: Forecast of Europe (in USD Bn)
- 2.5 Exhibit 2.5: Forecast of Asia Pacific (in USD Bn)
- 2.6 Exhibit 2.6: Forecast of Latin America (in USD Bn)
- 2.7 Exhibit 2.7: Forecast of Middle East & Africa (in USD Bn)
- 3.8 Exhibit 3.8: Forecast of Immunoassays (in USD Bn)
- 3.9 Exhibit 3.9: Forecast of Molecular Assays (in USD Bn)
- 3.10 Exhibit 3.10: Forecast of The Core Lab (Clinical Chemistry) (in USD Bn)
- 3.11 Exhibit 3.11: Forecast of Point-of-Care (POC) Tests (in USD Bn)
- 3.12 Exhibit 3.12: Forecast of Microbiology and Virology (in USD Bn)
- 3.13 Exhibit 3.13: Forecast of Hematology (in USD Bn)
- 3.14 Exhibit 3.14: Forecast of Coagulation (in USD Bn)
- 3.15 Exhibit 3.15: Forecast of Histology and Cytology (in USD Bn)
- 3.16 Exhibit 3.16: Forecast of Blood Banking Services (in USD Bn)
- 4.17 Exhibit 4.17: Forecast of Infectious Diseases (in USD Bn)
- 4.18 Exhibit 4.18: Forecast of Oncology (in USD Bn)
- 4.19 Exhibit 4.19: Forecast of Cardiology (in USD Bn)
- 4.20 Exhibit 4.20: Forecast of Diabetes (in USD Bn)
- 4.21 Exhibit 4.21: Forecast of Other Applications (in USD Bn)
- 6.22 Exhibit 6.22: Forecast of North America (in USD Bn)
- 6.23 Exhibit 6.23: Forecast of United States (in USD Bn)
- 6.24 Exhibit 6.24: Forecast of Canada (in USD Bn)
- 6.25 Exhibit 6.25: Forecast of Rest of North America (in USD Bn)
- 6.26 Exhibit 6.26: Forecast of Europe (in USD Bn)
- 6.27 Exhibit 6.27: Forecast of Germany (in USD Bn)
- 6.28 Exhibit 6.28: Forecast of France (in USD Bn)
- 6.29 Exhibit 6.29: Forecast of United Kingdom (in USD Bn)
- 6.30 Exhibit 6.30: Forecast of Switzerland (in USD Bn)
- 6.31 Exhibit 6.31: Forecast of Netherlands (in USD Bn)
- 6.32 Exhibit 6.32: Forecast of Spain (in USD Bn)
- 6.33 Exhibit 6.33: Forecast of Rest of Europe (in USD Bn)
- 6.34 Exhibit 6.34: Forecast of Asia Pacific (in USD Bn)
- 6.35 Exhibit 6.35: Forecast of China (in USD Bn)
- 6.36 Exhibit 6.36: Forecast of Japan (in USD Bn)
- 6.37 Exhibit 6.37: Forecast of India (in USD Bn)
- 6.38 Exhibit 6.38: Forecast of South Korea (in USD Bn)
- 6.39 Exhibit 6.39: Forecast of Rest of Asia Pacific (in USD Bn)
- 6.40 Exhibit 6.40: Forecast of Latin America (in USD Bn)
- 6.41 Exhibit 6.41: Forecast of Brazil (in USD Bn)
- 6.42 Exhibit 6.42: Forecast of Argentina (in USD Bn)
- 6.43 Exhibit 6.43: Forecast of Rest of Latin America (in USD Bn)
- 6.44 Exhibit 6.44: Forecast of Middle East & Africa (in USD Bn)
- 6.45 Exhibit 6.45: Forecast of Saudi Arabia (in USD Bn)
- 6.46 Exhibit 6.46: Forecast of South Africa (in USD Bn)
- 6.47 Exhibit 6.47: Forecast of Rest of Middle East & Africa (in USD Bn)
Frequently asked questions
What is the size of the global in vitro diagnostics (IVD) market?
How did bioMérieux perform in FY2025?
Has the competitive landscape changed materially?
Which application segment is largest?
How many companies and countries does this report cover?
Research Methodology
All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.
Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.
Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.
Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.
CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.
All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.
On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.
Related reports
Navadhi Market Research · Healthcare & Medical DevicesGlobal Wireless Infusion Pump Safety Market Strategic Research Report
The global wireless infusion pump safety market occupies a critical intersection of medical device technology, patient safety infrastructure, and hospital informatio…
Navadhi Market Research · Healthcare & Medical DevicesGlobal Smart Medical Waste Segregation Market Strategic Research Report
The global smart medical waste segregation market occupies a critical intersection of healthcare infrastructure, environmental compliance, and industrial automation.…
Navadhi Market Research · Healthcare & Medical DevicesGlobal Microfluidic Point of Care Diagnostics Market Strategic Research Report
The global microfluidic point of care (POC) diagnostics market represents one of the most commercially consequential intersections of materials science, biomedical e…
Need a customized version?
Get country-, segment- or company-specific intelligence tailored to your exact requirements.
Request custom research →Request a free sample
Receive a sample of Global In Vitro Diagnostics (IVD) Market Strategic Research Report before you buy.
Customize This Report
Describe your specific requirements and our analysts will scope and deliver a tailored version.
Request Invoice
We will email a proforma invoice within 24 hours. Report access is granted upon payment confirmation.
Leading Brands in This Industry
